Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management. The MINERVA Trial - A Phase IV Trial

NCT05362760 is registered in ClinicalTrials.gov with Prof. Wolfgang Janni as lead sponsor.

NCT NCT05362760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05362760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management. The MINERVA Trial - A Phase IV Trial
Lead sponsor
Prof. Wolfgang Janni
Phase
Phase 4
Overall status
Recruiting
Start date
April 27, 2022
Completion date
April 30, 2029
Enrollment
300 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative metastatic breast cancer, hormone receptor-positive metastatic breast cancer